Compare Stocks → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:ARCTNASDAQ:ARQTNASDAQ:ENTANYSE:MYOV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AARCTArcturus Therapeutics$26.46+1.1%$33.94$17.52▼$43.81$712.30M2.6449,129 shs10,364 shsARQTArcutis Biotherapeutics$8.67+0.9%$10.18$1.76▼$15.21$839.34M1.144.57 million shs114,015 shsENTAEnanta Pharmaceuticals$12.52+0.3%$14.84$8.08▼$37.75$264.92M0.47251,087 shs3,270 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics-3.00%-0.57%-18.55%-17.50%-1.80%ARQTArcutis Biotherapeutics-1.83%-9.10%-7.34%+62.08%-38.20%ENTAEnanta Pharmaceuticals-3.41%-5.67%-21.76%+2.04%-63.88%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AARCTArcturus Therapeutics2.5157 of 5 stars3.52.00.00.02.13.30.6ARQTArcutis Biotherapeutics1.1011 of 5 stars3.41.00.00.00.02.50.6ENTAEnanta Pharmaceuticals3.6303 of 5 stars3.10.00.04.72.82.50.6MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AARCTArcturus Therapeutics3.00Buy$61.33131.80% UpsideARQTArcutis Biotherapeutics2.75Moderate Buy$26.56206.29% UpsideENTAEnanta Pharmaceuticals2.17Hold$19.3354.42% UpsideMYOVMyovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest MYOV, ARCT, ARQT, ENTA, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.002/23/2024ARQTArcutis BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $16.002/8/2024ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.002/8/2024ENTAEnanta PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$12.00 ➝ $11.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AARCTArcturus Therapeutics$169.93M4.19N/AN/A$10.42 per share2.54ARQTArcutis Biotherapeutics$59.61M14.08N/AN/A$0.94 per share9.22ENTAEnanta Pharmaceuticals$79.20M3.34N/AN/A$10.29 per share1.22MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AARCTArcturus Therapeutics-$29.73M-$1.04N/A10.02N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)ARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)ENTAEnanta Pharmaceuticals-$133.82M-$6.56N/AN/AN/A-187.77%-60.38%-32.29%5/13/2024 (Estimated)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ALatest MYOV, ARCT, ARQT, ENTA, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million 2/7/2024Q1 2024ENTAEnanta Pharmaceuticals-$1.18-$1.58-$0.40-$1.58$22.74 million$18.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40ARCTArcturus TherapeuticsN/A4.724.72ARQTArcutis Biotherapeutics2.287.086.80ENTAEnanta PharmaceuticalsN/A6.256.25MYOVMyovant SciencesN/A1.571.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%ARCTArcturus Therapeutics94.54%ARQTArcutis BiotherapeuticsN/AENTAEnanta Pharmaceuticals94.99%MYOVMyovant Sciences30.62%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%ARCTArcturus Therapeutics13.80%ARQTArcutis Biotherapeutics20.70%ENTAEnanta Pharmaceuticals13.64%MYOVMyovant Sciences1.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionableENTAEnanta Pharmaceuticals14521.16 million18.27 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableMYOV, ARCT, ARQT, ENTA, and AIMT HeadlinesSourceHeadlineSalvage RT After Prostatectomy Prevails in Long-Term Comparison With Adjuvant RTmedpagetoday.com - April 19 at 7:59 PMWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugsuk.finance.yahoo.com - April 18 at 9:20 AMResearchers discover urine-based test to detect head and neck cancereurekalert.org - April 16 at 2:43 PMSocial Sciences & Interdisciplinary Studiescsus.edu - April 4 at 11:01 PMRoivant reveals positive immune drug data, share buyback plansbiopharmadive.com - April 2 at 3:38 PMComputer Science on Campusbc.edu - March 15 at 9:42 AMExposure to Teratogenic Medicine Common Before Prenatal Caremedpagetoday.com - February 6 at 9:50 AM2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Yearforbes.com - January 15 at 2:17 PMGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Regionfinance.yahoo.com - January 11 at 8:54 PMReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executivesfinance.yahoo.com - January 3 at 9:54 AMVivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...dailymail.co.uk - December 28 at 3:21 PMSumitomo Pharma CEO Myrtle Potter Focuses On Leading By Examplehealthleadersmedia.com - December 22 at 9:52 AMMetastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsightfinance.yahoo.com - December 8 at 9:34 AMDespite Effective Therapies, Fibroid Care Still Lackingmedscape.com - November 27 at 4:27 PMNCCN Announces Funding for Advanced Prostate Cancer Research Projectsmarkets.businessinsider.com - November 21 at 9:43 AMBlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in ...br.advfn.com - November 14 at 7:11 PMNews - Orgovyxthepharmaletter.com - October 24 at 3:11 PMNews - Myovant Sciencesthepharmaletter.com - October 24 at 3:11 PMMyovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbarrons.com - October 22 at 10:14 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant ...bakersfield.com - October 3 at 7:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVbenzinga.com - September 26 at 8:57 PMSumitomo Sued Over Skadden’s Alleged Conflicts in Myovant Mergernews.bloomberglaw.com - September 14 at 3:31 PM4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chiefmarketwatch.com - September 12 at 6:07 PMHormone Sensitive Advanced Prostate Cancer Treatment Market Set to Soar at 7.2% CAGR, Exceeding US$ 24.94 Billion by 2033 | Says FMIfmiblog.com - September 8 at 6:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent Pullback3 A.I. Stocks to Watch Out For Not Named NVIDIA April 23, 2024 7:00 AMView 3 A.I. Stocks to Watch Out For Not Named NVIDIA Wayfair: Strengthening Fundamentals or Just a Short Squeeze? April 2, 2024 7:45 AMView Wayfair: Strengthening Fundamentals or Just a Short Squeeze? Can Netflix Stock Continue Into All-Time Highs After Earnings?April 18, 2024 7:32 AMView Can Netflix Stock Continue Into All-Time Highs After Earnings?Analysts Agree, This Could Be Tyson Stock’s Comeback YearApril 23, 2024 6:05 AMView Analysts Agree, This Could Be Tyson Stock’s Comeback YearAll Headlines Company DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Arcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Arcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Enanta PharmaceuticalsNASDAQ:ENTAEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Myovant SciencesNYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.